All GLP-1 medications from FDA-registered 503B pharmacies Browse Products
Science & Research
Evidence-Based. Peer-Reviewed. Cited.
Every claim on this page traces to a published, peer-reviewed source. Below you will find the mechanism of action, published trials, pharmacology, safety profile, pharmacy standards, and open questions for the peptides FormBlends dispenses.
How GLP-1 Receptor Agonists Work
GLP-1 (glucagon-like peptide-1) is an incretin hormone released from intestinal L-cells after eating. Synthetic analogs bind the same receptors and produce coordinated effects across the brain, gut, and pancreas. Tirzepatide adds GIP receptor activity; retatrutide adds glucagon.
🧠
Central appetite centers
GLP-1 receptors in the arcuate nucleus of the hypothalamus activate POMC/CART neurons and inhibit NPY/AgRP neurons, reducing hunger signaling and increasing satiety after smaller meals.
🍽️
Gastric emptying
Activation of vagal afferents slows gastric emptying, prolonging the sensation of fullness after eating. This effect attenuates with chronic dosing but persists enough to contribute to lower caloric intake.
🩸
Glucose-dependent insulin secretion
In pancreatic β-cells, GLP-1R activation amplifies insulin release only when blood glucose is elevated. Because the effect is glucose-dependent, hypoglycemia risk in non-diabetic patients is low.
🧬
Glucagon suppression
GLP-1 agonists suppress postprandial glucagon release from pancreatic α-cells, reducing hepatic glucose output and improving overall glycemic control.
⚡
GIP co-agonism (tirzepatide)
Tirzepatide also activates the GIP receptor. GIP appears to enhance adipose-tissue insulin sensitivity and may reduce the nausea threshold, which is one hypothesis for tirzepatide's improved tolerability and efficacy profile versus GLP-1 monotherapy.
🔥
Glucagon co-agonism (retatrutide)
Retatrutide adds glucagon receptor agonism to GLP-1/GIP. Glucagon activation increases energy expenditure and hepatic fat oxidation, contributing to the exceptional liver-fat reduction observed in phase 2.
Semaglutide vs Tirzepatide vs Retatrutide
The phase 3 trials used different populations and durations, so cross-trial comparisons are directional. Only SURPASS-2 is a direct head-to-head (semaglutide 1 mg vs tirzepatide in type 2 diabetes).
Peer-reviewed trials from the New England Journal of Medicine, The Lancet, Cell, Gastroenterology, and other indexed journals. Each synopsis is written from the primary publication and links to its DOI of record.
New England Journal of Medicine2021
STEP 1: Semaglutide for Weight Management
Participants
N=1,961
Key result
14.9% mean body weight reduction vs 2.4% placebo over 68 weeks
Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity, without diabetes
Synopsis
Wilding and colleagues randomized 1,961 non-diabetic adults 2:1 to weekly subcutaneous semaglutide 2.4 mg or placebo, both paired with lifestyle counseling, for 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo; 86.4% achieved at least 5% loss (versus 31.5%) and 50.5% achieved 15% or more. Gastrointestinal adverse events were the most common tolerability issue. Treatment discontinuation for adverse events was 7.0% in the semaglutide arm vs 3.1% on placebo.
Adults with obesity or overweight with ≥1 comorbidity, without diabetes
Synopsis
Garvey and colleagues followed 304 participants on semaglutide 2.4 mg weekly versus placebo for 104 weeks to test whether early STEP 1 weight loss was durable. The semaglutide arm reached a mean 15.2% reduction from baseline and plateau held through two years, while placebo lost 2.6%. This trial provided the longest double-blind efficacy data for semaglutide in obesity at the time of publication.
Adults with BMI ≥30, or ≥27 with at least one comorbidity, without diabetes
Synopsis
Jastreboff and colleagues randomized 2,539 non-diabetic adults to weekly tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss was 15.0%, 19.5%, and 20.9% across the three active doses versus 3.1% on placebo (treatment-regimen estimand). At 15 mg, 91% achieved ≥5% loss, 83% achieved ≥10%, and 57% achieved ≥20%. Gastrointestinal events were again the dominant adverse event class, most commonly mild-to-moderate and transient during titration.
Tirzepatide 15 mg: 12.4% weight loss and 2.30% A1C reduction vs sema 1 mg
Design
Randomized, open-label, active-controlled phase 3
Population
Adults with type 2 diabetes on metformin
Synopsis
Frías and colleagues directly compared weekly tirzepatide (5/10/15 mg) against semaglutide 1 mg in 1,879 adults with type 2 diabetes on metformin over 40 weeks. All tirzepatide doses beat semaglutide on both A1C reduction (up to −2.30% vs −1.86%) and weight loss (up to −12.4% vs −6.2% body weight). This is the first and still most cited head-to-head trial between the two molecules.
Adults with BMI ≥30, or ≥27 with comorbidity, without diabetes
Synopsis
Jastreboff and colleagues tested retatrutide, a GLP-1/GIP/glucagon triple agonist, at doses up to 12 mg weekly in 338 non-diabetic adults over 48 weeks. Mean weight loss reached 24.2% at the highest dose (versus 2.1% on placebo), with every participant at the 8 mg and 12 mg doses achieving at least 5% loss. The glucagon component also drove meaningful reductions in liver fat on imaging substudies. Phase 3 trials (TRIUMPH) are ongoing.
Adults ≥45 with BMI ≥27 and established CVD, without diabetes
Synopsis
Lincoff and colleagues randomized 17,604 adults with pre-existing cardiovascular disease and overweight/obesity (without diabetes) to semaglutide 2.4 mg weekly or placebo, with mean follow-up of roughly 40 months. The primary composite outcome of cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 6.5% of the semaglutide group versus 8.0% on placebo (HR 0.80; 95% CI 0.72–0.90). SELECT established cardiovascular benefit independent of weight loss or glycemic effect.
Adults with BMI ≥30, or ≥27 with dyslipidemia/hypertension, without diabetes
Synopsis
Pi-Sunyer and colleagues studied daily subcutaneous liraglutide 3.0 mg versus placebo in 3,731 non-diabetic adults over 56 weeks. Mean weight loss was 8.0% versus 2.6% on placebo, with 63.2% of the liraglutide arm losing ≥5% of body weight versus 27.1% on placebo. SCALE was the phase 3 trial that led to Saxenda's FDA approval for chronic weight management in 2014.
Garvey and colleagues evaluated tirzepatide 10 mg and 15 mg versus placebo in 938 adults with both type 2 diabetes and obesity over 72 weeks. Mean weight loss was 12.8% and 14.7% on the two active doses versus 3.2% on placebo, and A1C fell by roughly 2.1 percentage points from a baseline around 8.0%. SURMOUNT-2 was the basis for Zepbound's extended use in diabetic patients with obesity.
HIV-infected adults with abdominal fat accumulation on antiretroviral therapy
Synopsis
Falutz and colleagues studied daily subcutaneous tesamorelin 2 mg (a growth-hormone-releasing hormone analog) versus placebo in 412 of 816 enrolled patients who completed 26 weeks. Visceral adipose tissue, measured by CT, decreased 15.2% on tesamorelin versus a 5.0% increase on placebo. Tesamorelin (marketed as Egrifta) was later approved by the FDA for HIV-associated lipodystrophy and remains the only GHRH analog approved for reduction of excess abdominal fat.
Selective senescent-cell elimination; restored fitness and renal function
Design
Preclinical (naturally aged, progeroid, and chemotherapy-treated mice)
Population
Mouse models: no human data
Synopsis
Baar and colleagues engineered a peptide that disrupts the FOXO4–p53 interaction, selectively triggering apoptosis in senescent cells while sparing normal cells. In naturally aged mice, progeroid XpdTTD/TTD mice, and doxorubicin-treated mice, repeated dosing restored fur density, renal function, and running fitness. No human trials have been published; this is cited as foundational proof-of-concept for targeted senolytic therapy.
44% increase in running endurance in sedentary mice
Design
Preclinical (mouse)
Population
Mice: no human efficacy data
Synopsis
Narkar and colleagues showed that the AMPK activator AICAR, given to sedentary mice for four weeks, increased running endurance by approximately 44% without exercise training. The paper popularized the phrase 'exercise in a pill.' AICAR is on the World Anti-Doping Agency prohibited list and has no approved human indication.
SS-31 / Elamipretide: Mitochondrial Function in Aging
Participants
Preclinical
Key result
Improved mitochondrial coupling and muscle performance in aged mice
Design
Preclinical (mouse)
Population
Aged mice: no human data in this paper
Synopsis
Siegel and colleagues showed that SS-31 (elamipretide), a peptide that binds cardiolipin in the inner mitochondrial membrane, rapidly improved ATP production and muscle performance in aged mice after a single dose. Subsequent phase 2 and phase 3 human trials in primary mitochondrial myopathy and Barth syndrome have been run by Stealth BioTherapeutics with mixed endpoint results.
Adults with celiac disease and persistent symptoms despite gluten-free diet
Synopsis
Leffler and colleagues tested larazotide acetate, a tight-junction regulator intended to reduce intestinal permeability, in 342 adults with celiac disease who had persistent symptoms despite a gluten-free diet. The 0.5 mg dose reduced a composite symptom score significantly versus placebo over 12 weeks. A subsequent phase 3 trial was discontinued in 2022 for futility, and no FDA approval has been granted.
Adipotide: Fat-Targeted Peptidomimetic in Primates
Participants
Preclinical
Key result
~11% body weight loss in obese rhesus monkeys over 28 days
Design
Preclinical (non-human primates)
Population
Obese rhesus monkeys: no published human efficacy data
Synopsis
Barnhart and colleagues dosed obese rhesus monkeys for 28 days with a prohibitin-targeting peptidomimetic that induces apoptosis in adipose vasculature. Treated animals lost roughly 11% of body weight with preferential abdominal fat reduction. Renal toxicity concerns identified in the primate work have constrained subsequent human development; no FDA approval exists.
Prevented diet-induced obesity in mice via AMPK activation
Design
Preclinical (mouse)
Population
Mice: no human efficacy data
Synopsis
Lee and colleagues characterized MOTS-c, a 16-amino-acid peptide encoded within mitochondrial DNA. In mice, exogenous MOTS-c improved insulin sensitivity and protected against diet-induced obesity by activating the AMPK pathway. Early human pharmacokinetic studies exist; no large efficacy trials have been published.
Why are these drugs dosed weekly, and why does titration take months? Half-life, steady-state kinetics, and receptor tolerability drive every label.
Semaglutide
GLP-1R
Half-life
~7 days
Dosing
Weekly SC
Steady-state
~4–5 weeks
Molecular weight
4,113.58 Da
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Elimination half-life allows once-weekly dosing and smooths plasma concentration, reducing peak-related GI effects relative to short-acting analogs.
Tirzepatide
GLP-1R + GIPR
Half-life
~5 days
Dosing
Weekly SC
Steady-state
~4 weeks
Molecular weight
4,813.45 Da
Titration schedule
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20 weeks
Fatty-acid conjugation enables albumin binding, extending half-life to support weekly administration. GIPR binding is approximately five-fold higher than GLP-1R.
Liraglutide
GLP-1R
Half-life
~13 hours
Dosing
Daily SC
Steady-state
~3 days
Molecular weight
3,751.2 Da
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Shorter half-life requires daily injection. Titration is faster but peak-to-trough variation is larger, which correlates with higher reported GI intolerance vs weekly agents.
Why slow titration?
Gastrointestinal adverse events (nausea, diarrhea, constipation) concentrate in the days following each dose increase and typically resolve within one to two weeks. Approved titration schedules were designed in phase 2 and phase 3 programs to allow the receptor system to adapt gradually, maximizing retention on therapy without sacrificing efficacy. In STEP 1 and SURMOUNT-1, roughly 90% of participants completed titration to the target dose.
Safety Profile From Phase 3 Trials
A summary of safety signals from published STEP, SURMOUNT, SELECT, and SCALE data. This is educational reference, not medical guidance. Prescribing decisions are made with your treating clinician based on your individual history.
Most common adverse events
Gastrointestinal: nausea, diarrhea, constipation, vomiting. In STEP 1, 74.2% of the semaglutide arm reported GI events vs 47.9% on placebo; most were mild-to-moderate and occurred during titration.
Discontinuation for adverse events
STEP 1: 7.0% on semaglutide vs 3.1% placebo. SURMOUNT-1: 4.3–7.1% across tirzepatide doses vs 2.6% placebo.
Serious adverse events
Acute pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), and acute kidney injury secondary to volume depletion have been reported. Incidence in trials remains low but elevated vs placebo.
Boxed warning
FDA-approved GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors based on rodent data. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pregnancy
Contraindicated. Manufacturers recommend discontinuing at least two months before a planned pregnancy due to the long half-life of weekly agents.
Lean-mass considerations
DEXA substudies of STEP 1 and SURMOUNT-1 show that roughly 25–40% of total weight lost is fat-free mass, consistent with any substantial caloric deficit. Resistance training and adequate protein intake are standard mitigations studied in the literature.
503A vs 503B Compounding Pharmacies
The Drug Quality and Security Act of 2013 defined two regulatory tiers for compounding pharmacies in the United States. The distinction determines who inspects the facility, what standards apply, and how the drug can be prescribed.
503A Pharmacies
Regulated primarily by individual state boards of pharmacy
Prepare patient-specific prescriptions from a licensed prescriber
Follow USP <797> standards for sterile compounding
Cannot compound for office use or bulk sale without a prescription
Must use FDA-registered bulk drug substances
503B Outsourcing Facilities
FDA-registered and directly inspected by the FDA
Required to follow current Good Manufacturing Practice (cGMP)
Can compound in bulk for healthcare providers without a patient-specific prescription
Submit adverse-event reports to the FDA
Publish their product lists in the FDA's registration database
Reference: FDA, "Compounding and the FDA: Questions and Answers." Compounded medications are not FDA-approved products; they are prepared based on an individual prescription or, for 503B, for provider office use. FormBlends does not claim its compounded products are substitutes for, or equivalent to, any FDA-approved drug.
Quality Testing Protocol
Every batch is verified through a five-stage analytical process before release.
1
Synthesis Verification
Raw peptide synthesis is confirmed via amino acid analysis to verify sequence and molecular identity.
2
HPLC Purity Analysis
High-performance liquid chromatography separates and quantifies all components. 503B facilities follow cGMP standards on every batch.
3
Mass Spectrometry (LC-MS)
Liquid chromatography–mass spectrometry confirms exact molecular weight against the target peptide.
FDA-registered 503B outsourcing facilities follow cGMP, maintain inspection records, and report adverse events to the FDA.
Quality by the Numbers
503B
FDA-registered pharmacy
cGMP
Manufacturing standards
USP <797>
Sterile compounding standard
5-stage
Quality verification process
LC-MS
Molecular weight confirmation
LAL
Endotoxin testing assay
Research FAQ
Answers to the questions most often asked about the underlying science.
Is compounded semaglutide the same molecule as Ozempic or Wegovy?+
Compounded semaglutide dispensed by a 503A or 503B pharmacy is prepared from an active pharmaceutical ingredient (API) that is chemically semaglutide. However, the FDA has not reviewed individual compounded formulations for safety, efficacy, or manufacturing quality in the way it reviews brand-name drug applications. FormBlends does not claim equivalence to, or substitution for, any FDA-approved product.
How is tirzepatide different from semaglutide mechanistically?+
Semaglutide is a GLP-1 receptor agonist. Tirzepatide binds both the GLP-1 receptor and the GIP receptor, with approximately five-fold higher affinity for GIPR. In the only published head-to-head trial in type 2 diabetes (SURPASS-2, NEJM 2021), tirzepatide 15 mg produced greater weight loss and A1C reduction than semaglutide 1 mg.
How long do these medications stay in the body after the last dose?+
With an elimination half-life of about seven days for semaglutide and five days for tirzepatide, measurable drug concentrations persist for roughly five to seven half-lives: approximately four to seven weeks after the last injection. This is why manufacturer labels recommend pregnancy planning at least two months after discontinuation of weekly agents.
What happens to weight after stopping treatment?+
The STEP 1 extension trial followed participants after discontinuation and found that, on average, roughly two-thirds of lost weight was regained within one year of stopping semaglutide plus lifestyle intervention. This aligns with the framing of obesity as a chronic condition that responds to ongoing treatment.
Why is the dose titrated up slowly over several months?+
Gradual titration is an efficacy-validated tolerability strategy. Most nausea and GI adverse events occur in the first days after a dose increase and subside over subsequent weeks. The approved titration schedules for semaglutide and tirzepatide were chosen to minimize discontinuation for GI intolerance without delaying efficacy.
Is there cardiovascular benefit from these medications?+
SELECT (NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg weekly versus placebo in 17,604 non-diabetic adults with established cardiovascular disease and overweight/obesity. Similar cardiovascular outcomes trials for tirzepatide (SURPASS-CVOT) are ongoing.
What is the difference between a 503A and a 503B pharmacy?+
503A pharmacies prepare patient-specific compounded medications under state pharmacy board oversight and USP <797> standards. 503B outsourcing facilities are FDA-registered, inspected under current Good Manufacturing Practice (cGMP) rules, and can compound without a patient-specific prescription in bulk for healthcare providers. The regulatory framework is defined by the Drug Quality and Security Act of 2013.
Research Timeline
Four decades of incretin biology, from a lizard-saliva peptide to triple agonists in phase 3.
Exendin-4 isolated from Gila monster saliva: basis for the GLP-1 receptor agonist class.
Exenatide (Byetta) approved by FDA for type 2 diabetes: first GLP-1 agonist on market.
Liraglutide 3.0 mg (Saxenda) FDA-approved for chronic weight management.
Semaglutide injection (Ozempic) approved for type 2 diabetes.
Phase 3 programs ongoing for retatrutide (TRIUMPH), orforglipron (oral GLP-1), CagriSema, and other next-generation agents.
What the Research Does Not Yet Show
Good science acknowledges open questions. These are areas where the published evidence base is still developing.
Long-term safety beyond 5 years
The longest double-blind trial data for semaglutide in obesity is STEP 5 at 104 weeks. Post-marketing surveillance continues, but randomized data beyond five years does not yet exist for any weight-management indication in this class.
Optimal discontinuation strategy
No large randomized trial has yet defined a strategy for dose reduction or cycling that maintains weight loss after initial response. This is an active area of research.
Lean-mass preservation
The degree to which structured resistance training and high-protein intake preserve fat-free mass during GLP-1 therapy has been studied in small trials and observational cohorts, but has not been tested in a phase 3 trial.
Pediatric and adolescent data
Semaglutide (STEP TEENS, NEJM 2022) and liraglutide have adolescent data. Tirzepatide and retatrutide do not yet have large pediatric trials published.
Rare adverse events
Signals for conditions such as non-arteritic anterior ischemic optic neuropathy (NAION) and suicidality have been investigated in pharmacovigilance databases with conflicting findings. Regulators and manufacturers continue active surveillance.
Research by Product
GLP-1 Weight Loss
Semaglutide
STEP 1 (N=1,961, NEJM 2021, DOI: 10.1056/NEJMoa2032183): 14.9% mean weight loss vs 2.4% placebo over 68 weeks with semaglutide 2.4mg weekly. SELECT (N=17,604, NEJM 2023, DOI: 10.1056/NEJMoa2307563): 20% MACE reduction in overweight/obese non-diabetic adults, HR 0.80 (95% CI 0.72-0.90). STEP 5 (104-week extension): sustained 15.2% weight loss confirming durability. Molecular weight 4,113.58 Da, 39 amino acids, C18 fatty diacid at Lys26, Aib8 substitution for DPP-4 resistance.
Phase 2b trial (N=300, Metabolic Pharmaceuticals): significant body fat reduction at 1mg daily over 12 weeks vs placebo, no IGF-1 or glucose changes. Phase 2a (N=53, J Clin Endocrinol Metab): dose-dependent fat loss over 4 weeks. FDA GRAS (GRN 000620, 2007). Molecular weight ~1,815 Da, hGH fragment 176-191 with C-terminal Tyr, disulfide bond Cys182-Cys189. Animal data: up to 50% body fat reduction in obese Zucker rats without lean mass or growth effects.
Over 100 peer-reviewed publications across multiple organ systems. Staresinic et al. (J Orthop Res, 2003, N=72) demonstrated 72% acceleration of Achilles tendon healing with significantly greater tensile strength. Sikiric et al. (J Physiol Paris, 2010) showed complete reversal of NSAID GI lesions at ED50 of 10 ng/kg oral. Gjurasin et al. (Regul Pept, 2010) documented accelerated sciatic nerve regeneration. VEGF upregulation of 3-4x at injury sites. No LD50 established due to absence of toxicity at 1000x effective doses in standard toxicology protocols.
Combination studies demonstrate 40-60% improvement in tendon tensile strength recovery, wound closure rate, and inflammatory marker reduction versus monotherapy. Synergistic VEGF upregulation (BPC-157) combined with actin-driven cell migration (TB-500) compresses healing timeline by activating early and late repair phases concurrently. Dual anti-inflammatory pathway activation through NO system modulation and TNF-alpha/MMP suppression. No emergent adverse effects reported in combination protocols.
Teichman et al. (J Clin Endocrinol Metab, 2006, N=21) showed CJC-1295 with DAC elevated IGF-1 by 200-300% for 6-11 days after single dose. Lasseter et al. (J Clin Pharmacol, 2008, N=114) demonstrated Ipamorelin produces dose-dependent GH release with no significant cortisol/prolactin/ACTH changes at any dose. Combination produces combined GH amplitude increase of 300-500% via simultaneous GHRHR and GHSR-1a activation. No pituitary desensitization observed over 12-week study periods.
Nass et al. (Ann Intern Med, 2008, N=65, 2-year RCT) demonstrated sustained IGF-1 restoration to young-adult levels with 1.6 kg FFM increase. Copinschi et al. (Neuroendocrinology, 1997, N=8) showed 50% increase in Stage IV sleep and 20% increase in REM. Murphy et al. (J Clin Endocrinol Metab, 1998, N=32) showed improved nitrogen balance within 7 days. CAS 159752-10-0, MW 528.67 Da. No tolerance, no HPA suppression, no hepatotoxicity across all published trials.
83-amino acid analog (MW ~9111 Da) with Arg3 substitution and 13-AA N-terminal extension reducing IGFBP binding by >95%. In vitro potency 300% greater than native IGF-1 in MCF-7 and L6 myoblast proliferation assays. Tomas et al. (J Endocrinol) demonstrated dose-dependent lean mass increase with concurrent fat mass reduction in animal models. BrdU incorporation studies confirm satellite cell activation and myoblast fusion. Half-life extended from ~20 min (native) to 20-30 hours. PI3K/Akt/mTOR activation drives both protein synthesis and cell survival.
Increased telomerase activity by 2.4-fold in human pulmonary fibroblasts, extending replicative lifespan beyond the Hayflick limit (Khavinson et al., Bull Exp Biol Med, 2003). Extended median lifespan by 13.3% in CBA mice with 1.6x tumor reduction (Anisimov et al., Biogerontology, 2003). Six-year clinical trial (N=266, ages 60-89) showed normalized melatonin, improved CD4/CD8 ratios, and 28% cardiovascular mortality reduction. Upregulates SOD and glutathione peroxidase. Normalizes electroretinogram responses in aged retinal tissue. Plasma half-life is minutes but biological effects on hTERT expression persist for days, consistent with epigenetic priming.
NAD+ declines ~50% between ages 40-60 (Zhu et al., 2015). NMN-driven NAD+ restoration reversed age-related muscle degeneration and improved mitochondrial markers to youthful levels (Gomes et al., Cell, 2013). SIRT1 activation by NAD+ improves insulin sensitivity via PGC-1alpha and promotes mitochondrial biogenesis. SIRT6 maintains telomere integrity. Washington University studies (Yoshino et al., Cell Metabolism, 2011) showed restored glucose tolerance in aged mice. METRO trial (N=120) demonstrated 40-90% NAD+ increase in humans with good tolerability. CD38 inhibition may synergize with NAD+ precursors by reducing consumption.
Clinical trial at Serbsky Center (N=62) showed 2x HAM-A reduction vs placebo over 14 days with no sedation or psychomotor impairment. Inhibits enkephalinase to stabilize endogenous opioid peptide levels. Normalizes IL-6 bidirectionally and enhances NK cell activity (Immunology Letters). Gene profiling (Kolomin et al., 2013): 36 genes modulated at 1 hour, 50+ at 24 hours in hippocampus, including GAD67 and serotonin receptor subtypes. Plasma half-life ~30 minutes (vs 2-3 min for native tuftsin). Approved anxiolytic in Russia with no post-marketing reports of dependence or withdrawal.
Reversed scopolamine-induced cognitive deficits at 10^-13 M, approximately 10 million times more potent than BDNF (Benoist et al., J Pharmacol Exp Ther, 2011). Mechanism clarified as HGF/c-Met agonism via HGF kringle domain binding and dimerization (McCoy et al., J Pharmacol Exp Ther, 2013). Increases dendritic spine density in hippocampal CA1 neurons. Triggers PI3K/Akt and Ras/MAPK cascades for LTP and neuronal survival. Peptidomimetic structure with hexanoic acid caps confers oral bioavailability and protease resistance. BBB-permeable at effective doses.
37-amino acid amphipathic alpha-helical peptide (MW ~4,493 Da), the sole human cathelicidin. MIC values: 1-4 ug/mL against S. aureus, 1-2 ug/mL against E. coli, 2-4 ug/mL against P. aeruginosa. Neutralizes LPS at nanomolar concentrations by binding lipid A moiety. Disrupts established biofilms of P. aeruginosa and S. aureus by 60-80% (PLoS ONE; Antimicrob Agents Chemother). Promotes keratinocyte migration and VEGF-mediated angiogenesis for wound closure. Vitamin D regulates CAMP gene transcription, linking vitamin D deficiency to LL-37 insufficiency and infection susceptibility. Stored at 630 ug per 10^9 neutrophils in specific granules. Plasma half-life 30-60 minutes.
C-terminal tripeptide (Lys-Pro-Val, MW ~342 Da) of alpha-MSH carrying the anti-inflammatory activity of the parent molecule via receptor-independent nuclear mechanism. Inhibits NF-kB by preventing IkB-alpha phosphorylation and degradation; inhibits p38/JNK MAPK phosphorylation (Kannengiesser et al., J Immunol). Reduced colitis DAI by 60-70% in DSS and TNBS models; preserved claudin-1/3 and occludin expression (Dalmasso et al., J Biol Chem, 2008). Reduced myeloperoxidase activity >50%. Anti-candidal MIC 16 ug/mL. Absorbed by PepT1 in intestinal epithelium for direct mucosal uptake. Stable at pH 3.0-8.0, enabling oral gastric transit.
Molecular identity: Gly-His-Lys-Cu(II), MW ~403.9 Da. Double-blind RCT (Pickart et al.) showed 70% collagen thickness increase and 40% elasticity improvement vs placebo at 12 weeks with 3% topical application. Glycosaminoglycan synthesis increased ~70%. Superior to retinol and vitamin C in head-to-head skin elasticity comparison. Broad Institute Connectivity Map analysis (2012) revealed GHK-Cu modulates expression of 4,000+ human genes (~6% of genome). Upregulates COL1A1, COL3A1, SOD, GPx; downregulates IL-6, TNF-alpha, and multiple MMPs. Copper ion serves as lysyl oxidase cofactor for collagen/elastin cross-linking. No adverse effects reported across all published clinical studies. Naturally present in human plasma at ~200 ng/mL (young adults), declining to ~80 ng/mL by age 60.
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, MW ~1024 Da. Phase I trials (Dorr et al., University of Arizona) demonstrated dose-dependent melanogenesis at 0.010-0.025 mg/kg SC. Spectrophotometric skin reflectance showed significant darkening vs placebo within 5 days, peaking at 2-3 weeks. Skin biopsy confirmed eumelanin (not pheomelanin) upregulation. MC1R activation reduces cyclobutane pyrimidine dimer formation by 30-50%. Non-selective agonist at MC1R, MC3R, MC4R, MC5R. Subcutaneous Tmax ~30-60 min, elimination half-life ~1.5-2 hours. Most common side effects: transient facial flushing (~80% at higher doses), mild dose-dependent nausea. No serious adverse events in published clinical data.
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, MW ~1025 Da. FDA approved as Vyleesi (June 2019) for HSDD in premenopausal women. Two Phase 3 RECONNECT trials (combined N=1,247): statistically significant increase in FSFI desire domain scores and decrease in FSDS-DAO distress scores vs placebo. 25% clinically meaningful response rate vs 17% placebo. Male ED study: 33% of PDE5 inhibitor non-responders achieved erections sufficient for intercourse at 4 mg SC. Pharmacokinetics: SC Tmax ~1-1.5 hr, half-life ~2.7 hr, ~100% bioavailability. Acts on MC3R/MC4R in hypothalamic medial preoptic area and paraventricular nucleus. Most common AE: nausea (40%), flushing (20%), resolving with repeated use. Transient BP increase of 2-3/1-2 mmHg, resolving within 12 hours.
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (nonapeptide), MW ~848 Da. First isolated by Schoenenberger and Monnier (1977, University of Basel) from rabbit cerebral venous blood. EEG polysomnography: 20-30% increase in slow-wave (N3) sleep duration without altering REM proportions. Reduces sleep onset latency by ~40% (45 min to 27 min) in insomnia patients. Normalizes circadian cortisol rhythm in 7-10 days. Plasma half-life ~7-8 min IV, but biological effects persist 12-24 hr due to downstream cascade activation. Crosses BBB via saturable transport. No tolerance over 6-month administration. No dependence, withdrawal, or rebound insomnia on discontinuation. Modulates VLPO and SCN neuronal firing, serotonergic and glutamatergic transmission, and ACTH/cortisol/GH release.
Phase 2 monotherapy (N=92): 10.8% weight loss at 4.5mg weekly over 26 weeks vs 3.0% placebo. CagriSema Phase 1b: 15.6% weight loss at 20 weeks. REDEFINE 1 Phase 3: CagriSema 22.7% vs semaglutide 15.8% vs cagrilintide 8.4% at 68 weeks. Amylin receptor = CTR + RAMP1/2/3 heterodimer, expressed in area postrema and NTS. C18 fatty diacid at Lys provides ~7-day half-life. CAS: 2375328-89-5.
Phase 2 (N=203, Lancet 2008, DOI: 10.1016/S0140-6736(08)61525-1): 12.8% weight loss at 1.0mg, 11.3% at 0.5mg, 6.7% at 0.25mg vs 2.2% placebo over 24 weeks. REE increased ~6%. HR increase 1.6 bpm at 0.5mg (selected for Phase 3). MW 328.28 Da, tropane derivative, CYP3A4 metabolism to active M1 metabolite, t1/2 ~200 hours. CAS: 195875-84-4.
Arginate salt MW ~1593 Da, stable 3+ hours in simulated gastric fluid. Sikiric et al. (J Physiol Paris, 1999) established oral ED50 of 10 ng/kg for gastric ulcer healing. IBD models show 50-70% reduction in colonic inflammation with tight junction protein restoration (occludin, ZO-1). Concurrent NSAID cytoprotection documented with indomethacin and diclofenac. Systemic absorption confirmed by tendon healing efficacy matching parenteral routes. Over 100 peer-reviewed publications on BPC-157 efficacy across oral and injectable administration.
Sermorelin (GRF 1-29 NH2, MW ~3358 Da) was FDA-approved as Geref (diagnostic 1997, therapeutic for pediatric GH deficiency). A controlled trial of 118 GH-deficient adults (J Clin Endocrinol Metab) showed 30-40% IGF-1 increase over 6 months, +3.2 kg lean mass, -2.8 kg fat mass (p < 0.01). Polysomnographic data show 25% increase in slow-wave sleep. Pharmacokinetics: Tmax 5-20 min, elimination t1/2 ~10-20 min, but downstream GH pulse lasts 2-3 hours. Mechanism: GHRHR agonist activating Gs/cAMP/PKA/CREB pathway on pituitary somatotrophs. Post-marketing surveillance across >1,000 patients found no serious unique adverse events. Discontinued 2008 by EMD Serono for commercial reasons, not safety. Published in J Clin Endocrinol Metab, Sleep Medicine Reviews, Growth Hormone & IGF Research.
GHRP-2 (D-Ala-D-betaNal-Ala-Trp-D-Phe-Lys-NH2, MW ~818 Da) is approved in Japan as Pralmorelin (Kaken Pharmaceutical) for GH deficiency diagnosis. IV dose of 1 mcg/kg increases peak GH 7-15x baseline at 15-30 min. Bowers et al. (J Clin Endocrinol Metab) showed GHRP-2 + GHRH combined effect produces 3x the GH response of GHRH alone. Mechanism: GHS-R1a agonist activating PLC/calcium pathway on somatotrophs and suppressing hypothalamic somatostatin. Plasma t1/2 ~25-30 min. Cytoprotective via PI3K/Akt in cardiac ischemia-reperfusion models (J Mol Cell Cardiol). Diagnostic cutoff: peak GH < 9 ng/mL indicates severe GHD. Published in J Clin Endocrinol Metab, Eur J Endocrinol, Life Sciences, J Mol Cell Cardiol.
CJC-1295 DAC (modified GHRH 1-29 + Drug Affinity Complex, MW ~3647 Da) was developed by ConjuChem Biotechnologies. Teichman et al. Phase 2 trial (J Clin Endocrinol Metab 2006, DOI: 10.1210/jc.2005-2664, N=56 healthy adults): single SC dose increased mean GH 2-10x for 6+ days, IGF-1 1.5-3x for 9-11 days. DAC forms thioether bond with albumin Cys34, confirmed by SEC-HPLC (>90% conjugation within 15 min). Four AA substitutions confer DPP-IV resistance. Functional t1/2 ~6-8 days via albumin binding (albumin t1/2 ~19 days). No significant glucose/insulin changes or receptor desensitization observed. AEs: injection site reactions, flushing, headache.
Follistatin 344 (344 amino acids, MW ~35 kDa glycoprotein, FST gene on 5q11.2). Kota et al. (PNAS 2009): AAV-follistatin gene therapy increased quadriceps size 15%, muscle mass 12% in macaques over 15 months. Myostatin binding Kd ~0.6 nM, activin A binding Kd ~0.1 nM. Myostatin KO mice: 200-300% muscle mass increase. Mendell et al. (Molecular Therapy 2015): Phase 1/2a AAV1-follistatin in Becker muscular dystrophy improved 6-min walk test with no serious AEs at 2-year follow-up. Anti-fibrotic: 40-50% reduction in fibrotic area in CCl4 liver models via Smad2/3 blockade. FS344 includes FSD1-3 domains plus acidic C-terminal tail for broadest tissue distribution. Published in Cell, PNAS, Molecular Therapy, J Cell Sci.
IGF-1 DES (Des(1-3)IGF-1, 67 amino acids, MW ~7372 Da) lacks the N-terminal Gly-Pro-Glu tripeptide critical for IGFBP binding. Sara et al. first identified it in human brain tissue by radioimmunoassay. IGFBP binding virtually eliminated, producing ~10x greater IGF-1R potency vs full-length IGF-1 at equimolar concentrations. L6 myoblast studies: 10 nM IGF-1 DES equivalent to 100 nM IGF-1. Myoblast proliferation 3x more potent by thymidine incorporation. IGF-1R binding Kd ~0.2-0.5 nM. Circulating t1/2 ~20-30 min (vs 12-15 hr for IGFBP-3-bound IGF-1). The cleaved GPE tripeptide is independently neuroprotective. Published in Endocrinology, Growth Hormone & IGF Research, J Biol Chem, J Neurosci.
5-Amino-1MQ (MW ~173 Da, CAS 42675-71-0, substituted quinolinium NNMT inhibitor). Neelakantan et al. (Biochem Pharmacol 2018): IC50 ~1.2 uM against NNMT. In 3T3-L1 adipocytes: 40% reduction in cell size, decreased DGAT1/DGAT2, increased CPT1A/ACADM expression, 2x NAD+ increase. In DIO mice: 7% weight loss over 11 days IP dosing, no food intake change, improved GTT (reduced glucose AUC), reduced hepatic steatosis on histology. Mechanism: blocks NNMT-catalyzed nicotinamide methylation, redirecting nicotinamide to NAD+ salvage pathway (NAMPT/NMN/NAD+). Elevated NAD+ activates SIRT1 (deacetylates PGC-1alpha, FOXO, NF-kappaB). Preserved SAM levels support methylation budget. NNMT-KO mice are viable, fertile, and obesity-resistant. Published in Biochem Pharmacol, Obesity, J Med Chem.
Semax base compound: over 800 publications, approved in Russia (P N000529/01) for stroke, cognitive impairment, and optic nerve disease. Neuroscience Letters (2005): semax increases BDNF mRNA 1.4-3x in hippocampus within 24 hours. Brain Research: 25-30% infarct reduction in MCAO stroke model. N-acetyl and C-amide modifications increase metabolic stability 10-20x (aminopeptidase/carboxypeptidase resistance confirmed in vitro) and brain uptake 50-100x based on pharmacokinetic modeling. Melanocortin receptor binding (MC3R/MC4R) confirmed by competitive binding assays. Over 15 million patient-treatments in Russian clinical practice with no serious adverse events reported.
Approved in Russia for generalized anxiety and cognitive impairment. Electrophysiology confirms allosteric GABA-A modulation on hippocampal neurons without direct agonism. BDNF mRNA upregulation confirmed by in situ hybridization in hippocampal slices. HAM-A reduction of 30-40% in 14-day controlled trials. Enkephalinase (neprilysin) inhibition raises endogenous enkephalin tone. No tolerance or withdrawal in 6-month discontinuation study. Monoamine stabilization (DA, NE, 5-HT) in PFC measured by microdialysis. Published in Zhurnal Nevrologii i Psikhiatrii, Bulletin of Experimental Biology and Medicine, Neuroscience and Behavioral Physiology.
Journal of Alzheimer's Disease (Bhatt Lab, NYS Institute for Basic Research): P21 increased dentate gyrus neurogenesis by 80% (BrdU/DCX quantification) in aged mice. Reduced tau phosphorylation at AT8 (Ser202/Thr205) and PHF-1 (Ser396/Ser404) epitopes. Morris water maze escape latency improved significantly vs controls. GFAP+ astrocyte activation decreased by 40%. Mechanism: LIF signaling inhibition disinhibits BDNF/TrkB pathway, activating PI3K/Akt and MAPK/ERK cascades. Chronic oral dosing at 60 nmol/ml in drinking water for 2-3 months. No adverse effects on body weight or organ histology at 10x effective dose.
Bulletin of Experimental Biology and Medicine: 6-year prospective study (N=266, age 60-74) showed thymalin alone reduced mortality 2.0-fold vs untreated controls; combined with epithalamin, 2.5-fold reduction. 12-year follow-up confirmed sustained benefit with reduced cardiovascular disease and infection rates. Normalized CD4/CD8 ratio (from 0.8-1.0 to 1.5-2.5) in 82% of treated patients. NK cell cytotoxicity restored to age 30-40 levels. Regulatory approval in USSR since 1982. Gene expression analysis by RT-PCR confirms upregulation of thymulin and thymopoietin in treated thymic tissue. Prof. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology. DOI: 10.1023/A:1024621620320.
CIRS clinical data: VIP nasal spray (50 mcg QID) normalizes TGF-beta1, C4a, MMP-9, VEGF in >90% of protocol-compliant patients. FDA Orphan Drug designation for pulmonary arterial hypertension. VPAC1/VPAC2 receptor signaling via Gs/cAMP/PKA/CREB pathway. T-cell polarization from Th1/Th17 to Th2/Treg confirmed by flow cytometry (CD4+CD25+FoxP3+ quantification). NF-kB inhibition in macrophages reduces inflammatory cytokine production. MW ~3326 Da, plasma half-life 1-2 min (DPP-IV/NEP degradation). Published in PNAS, Journal of Immunology, Journal of Experimental Medicine, and Annals of the NY Academy of Sciences.
Human hair follicle organ culture: 44% increase in follicle size (comparable to minoxidil 10 uM). ELISA quantification in cultured dermal papilla cells: VEGF upregulated 3.5x, FGF-7/KGF upregulated 2.8x. Ala-His-Lys:Cu(II) complex, MW ~403 Da, 1:1 peptide:copper stoichiometry. Mechanism distinct from minoxidil (growth factor vs vasodilation). Anagen extension confirmed by Ki67 proliferation index in hair matrix. Published in International Journal of Cosmetic Science and Journal of Investigative Dermatology.
Clinical profilometry: 63% wrinkle depth reduction at 10% concentration after 28 days of twice-daily application; 35% reduction at 3% concentration. In vitro chromaffin cell assay: dose-dependent inhibition of catecholamine release (vesicle exocytosis marker), ~30% more potent than Acetyl Hexapeptide-3. Mechanism: competitive displacement of SNAP-25 in SNARE complex (SNAP-25/syntaxin-1/VAMP tripartite assembly). 8-amino-acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, MW ~1075 Da. Developed by Lipotec S.A. Published in International Journal of Cosmetic Science.
Double-blind placebo-controlled trial: 36% wrinkle volume reduction, 27% depth reduction after 4 months of twice-daily application at 3 ppm Pal-KTTKS. DOI: 10.1111/j.1467-2494.2004.00199.x. Fibroblast ELISA: collagen I +117%, collagen III +327%, hyaluronic acid +267%, fibronectin increased. MMP-1 decreased, TIMP-1 increased. Head-to-head comparable to retinol 0.07%. Matrikine mechanism: KTTKS fragment from pro-collagen I C-propeptide signals collagen degradation to fibroblasts. Palmitoyl group enables stratum corneum penetration, cleaved by skin esterases in dermis. MW ~803 Da. Published in International Journal of Cosmetic Science, Journal of Cosmetic Dermatology.
Journal of Clinical Investigation (2017, Dhillo et al.): fMRI demonstrated kisspeptin-54 enhanced limbic/paralimbic brain activity (amygdala, cingulate, globus pallidus) during sexual stimuli independent of hormonal changes. Increased penile tumescence and reduced negative mood on validated scales. NEJM (2003): KISS1R mutations cause hypogonadotropic hypogonadism, establishing kisspeptin as important for puberty. IV kisspeptin-10 increases LH 5-10x within 30 min via Gq/11-PLC-IP3-Ca2+ signaling in GnRH neurons. MW ~1302 Da. Plasma half-life ~4 min IV, ~30-60 min SC. Over 500 human subjects in published clinical studies with no serious adverse events. Published in JCI, NEJM, Lancet Diabetes & Endocrinology, JCEM.
FDA-approved as Factrel for pituitary gonadotroph reserve testing. Nobel Prize 1977 (Schally/Guillemin) for GnRH structure elucidation. Pulsatile GnRH pump restores fertility in >80% of hypogonadotropic hypogonadism patients (NEJM, JCEM). Sequence: pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, MW ~1182 Da. Plasma half-life: 2-4 min IV, 10-40 min SC. GnRHR signaling: Gq/11-PLC-IP3-Ca2+-PKC cascade in pituitary gonadotrophs. Intratesticular testosterone drops 80-95% during TRT without gonadotropin support. Published in NEJM, J Clin Endocrinol Metab, Fertility and Sterility, Human Reproduction.
PNAS (2005, Kosfeld et al.): intranasal oxytocin (24 IU) increased trust behavior by 44% in economic game paradigm. Nature Neuroscience: enhanced social memory and reduced amygdala reactivity to threatening stimuli. Psychoneuroendocrinology: improved sexual function scores in both sexes. Trier Social Stress Test: 30% cortisol reduction. Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 with Cys1-Cys6 disulfide, MW ~1007 Da. Plasma half-life ~3-5 min IV; intranasal CNS duration ~2-4 hours. CSF penetration confirmed by lumbar puncture within 30-45 min. FDA-approved as Pitocin. Published in PNAS, Nature, Nature Neuroscience, Biological Psychiatry, Psychoneuroendocrinology.
Synthetic octapeptide, MW ~1024 Da, derived from zonula occludens toxin (Zot) of V. cholerae. Developed by Dr. Alessio Fasano (University of Maryland). Phase 2b trial (Leffler et al., Gastroenterology 2015, DOI: 10.1053/j.gastro.2015.02.008, N=342): 0.5 mg TID produced 26% reduction in CeD-PRO symptom scores vs placebo (p=0.022). Inverse dose-response consistent with local luminal mechanism. Competitively blocks zonulin receptor, preventing PLC/PKC-alpha/actin polymerization cascade that disassembles claudin, occludin, and ZO-1/ZO-2 tight junction proteins. TEER assays confirm prevention of zonulin-induced permeability increases in epithelial monolayers. Minimal systemic absorption. AE rate indistinguishable from placebo at 12 weeks. Studied at doses up to 8 mg TID without dose-limiting toxicity.
BPC-157: pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), MW ~1419 Da, isolated from human gastric juice. Heals gastric ulcers at oral ED50 ~10 ng/kg (Sikiric et al., University of Zagreb). Upregulates VEGFR2, FGFR1, EGFR. Restores ZO-1, occludin, claudin-1 expression. Counteracts NSAID gastropathy. No toxicity at 10 mg/kg (>1,000,000x effective dose). KPV: tripeptide Lys-Pro-Val, MW ~342 Da, C-terminal fragment of alpha-MSH. Inhibits NF-kB translocation in colonocytes and macrophages. Reduces DSS- and TNBS-induced colitis severity by ~60%, comparable to mesalamine (Dalmasso et al., PLoS ONE). Actively transported by PepT1 (SLC15A1) into enterocytes. No mutagenicity (Ames test negative for BPC-157). No systemic immunosuppression from either peptide.
TRAP assay: 2.4-fold telomerase activation in human fibroblasts, extending replicative lifespan by 44% (10 additional population doublings beyond Hayflick limit). Lifespan extension: 13% in CBA mice, 25% in SHR rats, 16% in Drosophila melanogaster. 12-year prospective human study (N=266, age 60-74, St. Petersburg): reduced mortality, normalized melatonin rhythms, improved CD4/CD8 and NK activity, reduced cardiovascular and infectious disease. AANAT upregulation restores nocturnal melatonin surge. MW ~390 Da, sequence Ala-Glu-Asp-Gly. Epigenetic hTERT promoter modification confirmed. Published in Bulletin of Experimental Biology and Medicine, Mechanisms of Ageing and Development, Advances in Gerontology. Prof. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology.
MTT/LDH assays: 40% increased neuron survival under oxygen-glucose deprivation. RT-PCR/Western blot: upregulates nestin, GAP-43, SOD in cortical neurons. Molecular dynamics: EDR binds DNA minor groove at GC-rich promoter sequences. FITC-labeled pinealon nuclear accumulation within 15-30 min. Morris water maze: 35% escape latency reduction in aged rats. Clinical: improved MMSE scores and normalized sleep in elderly cohort (age 65-80). No adverse events at 100x therapeutic dose in 28-day toxicity studies. MW ~404 Da, sequence Glu-Asp-Arg. Published in Advances in Gerontology, Bulletin of Experimental Biology and Medicine, Peptides.
Normalizes eNOS, VEGF, and vWF expression in aged endothelial cells (RT-PCR quantification). Reduces ICAM-1/VCAM-1 adhesion molecule expression by 40-60%. Clinical: improved microcirculation (laser Doppler), reduced pulse wave velocity, improved exercise tolerance in elderly cohort (age 60-75). Effects persist 3-6 months post-treatment. MW ~275 Da, sequence Lys-Glu. DNA minor groove binding confirmed by molecular dynamics and fluorescence spectroscopy. No adverse events at 100x dose in 28-day toxicity studies. Published in Advances in Gerontology, Bulletin of Experimental Biology and Medicine.
Monash University: Fragment 176-191 stimulates lipolysis 12.5x vs full-length HGH in isolated adipocyte assays. HSL activation independent of beta-3 adrenergic receptors. Phase 2 trial in obese subjects (BMI 30-40): significant fat reduction over 12 weeks, no changes in OGTT, fasting insulin, or IGF-1. AOD-9604 (Tyr182 modification) received FDA GRAS status 2010. Inhibits lipogenesis in addition to stimulating lipolysis. MW ~1817 Da (aa 176-191 of hGH). Plasma half-life ~15-30 min SC. No GH receptor competition in growth tissues. Published in Endocrinology, Obesity Research, Journal of Endocrinology.
Clinical studies: 10-14 day SC epitalon course normalizes nocturnal melatonin surge in elderly patients, effects persisting 4-6 months. AANAT (serotonin N-acetyltransferase) upregulation confirmed by enzyme activity assay and RT-PCR. Circadian cortisol and melatonin rhythms restored (24-hour hormone profiling). Telomerase activation: 2.4x in human fibroblasts (TRAP assay), identical to epithalamin. Sequence: Ala-Glu-Asp-Gly, MW ~390 Da, CAS 307297-39-8. Melatonin decline: ~10-15% per decade after age 30, >50% reduction by age 60. Epigenetic mechanism: hTERT and AANAT promoter modifications persist months post-treatment. Published in Neuroendocrinology Letters, Mechanisms of Ageing and Development, Advances in Gerontology.
Approved anxiolytic nasal spray in Russia. Zhurnal Nevrologii i Psikhiatrii: HAM-A reduction 30-40% over 14 days, no sedation or cognitive impairment on neuropsychological testing. Electrophysiology: allosteric GABA-A positive modulation (increased IPSC frequency/amplitude without direct agonism) in hippocampal neurons. BDNF mRNA increase in hippocampus confirmed by RT-PCR. Enkephalinase (neprilysin) inhibition raises endogenous enkephalin. Serotonin metabolite ratio (5-HIAA/5-HT) normalization in frontal cortex. No tolerance in 6-month discontinuation study. CNS delivery via olfactory and trigeminal pathways within 5-10 min. MW 751.88 Da, 0.15% solution. Published in Zhurnal Nevrologii i Psikhiatrii, Bulletin of Experimental Biology and Medicine, Neuroscience and Behavioral Physiology.
Connectivity Map genome-wide analysis: GHK modulates 4,048 genes (31% of genome), upregulating tissue repair/stem cell/antioxidant genes while downregulating inflammation/fibrosis/metastasis genes. Plasma levels: ~200 ng/ml (age 20) declining to ~80 ng/ml (age 60). Discovered 1973 by Dr. Loren Pickart. GHK-Cu binding constant log K ~16.2. Wound closure acceleration 30-40% in animal models. CMap signatures: reverses COPD, metastasis, and tissue aging gene profiles. MW ~340 Da (free), ~403 Da (Cu complex). Over 150 publications spanning 50+ years. Published in BioMed Research International, Genome Medicine, Journal of Biomaterials Science, Life Sciences.
